Clinical Trials

982 enrolled 15 charts

Prostatic Neoplasms

NCT03748641 2026-03-16

MAGNITUDE

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT05848011 2026-03-16

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

154 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT02123758 2026-03-13

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

57 enrolled

Prostatic Neoplasms

NCT04577833 2026-03-13

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Prostatic Neoplasms

NCT04662580 2026-03-13

ARX517

183 enrolled

Prostatic Neoplasms

NCT04623541 2026-03-04

EPCORE™ CLL-1

LymphoidOther hematologic neoplasm

195 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04542824 2026-03-03

EPCORE™ NHL-3

LymphoidOther hematologic neoplasm

78 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-03-03

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05888493 2026-02-20

LEDA

109 enrolled

Lymphoma, Follicular, Recurrence

NCT03407144 2026-02-19

MK-3475-667

340 enrolled

Hodgkin Disease

NCT04497844 2026-02-13

AMPLITUDE

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT06356129 2026-02-12

GOLSEEK-1

850 enrolled

Lymphoma

NCT03274492 2026-02-06

POLARIX

1,000 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT06097364 2026-02-06

OLYMPIA-2

733 enrolled

Lymphoma, Follicular, Recurrence

NCT06091865 2026-02-05

OLYMPIA-3

904 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06425302 2026-01-08

GOLSEEK-2

90 enrolled

Lymphoma, Lymphoma, Follicular

NCT03431350 2025-12-23

QUEST

136 enrolled 29 charts

Prostatic Neoplasms, Castration-Resistant

NCT06421935 2025-12-19

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

141 enrolled

Gynecologic

Ovarian Neoplasms

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT05371093 2025-10-15

ZUMA-22

231 enrolled

Lymphoma, Follicular

NCT04824092 2025-09-08

frontMIND

899 enrolled

Phase 2/3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03348670 2025-08-17

Drugs-SNPs

600 enrolled

Neoplasms, Prostatic Neoplasms

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

439 enrolled

Prostatic Neoplasms

NCT05673785 2025-07-14

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

52 enrolled

Lymphoma

NCT05288166 2025-06-27

CYCLONE 3

925 enrolled 12 charts

Phase 2/3 Active not recruiting

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT03706365 2025-04-20

CYCLONE 2

393 enrolled 23 charts

Prostatic Neoplasms

NCT05578976 2025-01-23

EPCORE DLBCL-2

900 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05201248 2025-01-07

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

49 enrolled

Neoplasms, Lymphoma, B-Cell

NCT04691804 2024-12-31

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

496 enrolled

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04231448 2024-12-05

DEB

423 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05406401 2024-10-15

waveLINE-007

60 enrolled